Background: Lichen sclerosus (LS) is a disease of the skin of unclear etiology that can occur in the foreskin. Topical therapy with corticosteroids is recommended, but they can have side effects. Objectives: We aimed to compare the effects of ozonides with vitamin E acetate (OZOILE) versus topical corticosteroid in children undergoing circumcision. Method: Twenty children undergoing circumcision were treated before surgery: 10 children with OZOILE cream and 10 with 0.1% mometasone furoate once a day for 7 days. Ten age-matched patients with LS of the foreskin without any treatment were recruited as controls. Transcript levels of proinflammatory and anti-inflammatory cytokines and e-cadherin were evaluated in removed foreskins by qRT-PCR. Results: OZOILE and steroid topical treatment produced a similar reduction of TNF-α and IL-1β mRNA levels in foreskins from patients with LS when compared to untreated patients (p < 0.001). OZOILE and steroid treatment caused an increase in the transcript levels of IL-13 and e-cadherin in the foreskin of patients affected by LS in comparison to untreated foreskin (p < 0.001). Conclusions: On the basis of our biochemical data, a randomized clinical trial might be useful to verify the actual clinical effect of OZOILE as alternative treatment to corticosteroids in children affected by LS of the foreskin.

Keywords:
Lichen sclerosus, Phimosis, Children, Stable ozonides, Vitamin E acetate, Corticosteroids
1.
Hallopeau H. Du lichen plan et particulièrement de sa forme atrophique: lichen plan scléreux.
Ann Dermatol Syphiligr (Paris)
. 1887; 8: 790–1.
2.
Bercaw-Pratt JL, Boardman LA, Simms-Cendan JS; North American Society for Pediatric and Adolescent Gynecology. Clinical recommendation: pediatric lichen sclerosus.
J Pediatr Adolesc Gynecol
. 2014 Apr; 27(2): 111–6.
3.
Powell J, Wojnarowska F. Childhood vulvar lichen sclerosus: an increasingly common problem.
J Am Acad Dermatol
. 2001 May; 44(5): 803–6.
4.
Powell JJ, Wojnarowska F. Lichen sclerosus.
Lancet
. 1999 May; 353(9166): 1777–83.
5.
Kiss A, Király L, Kutasy B, Merksz M. High incidence of balanitis xerotica obliterans in boys with phimosis: prospective 10-year study.
Pediatr Dermatol
. 2005 Jul-Aug; 22(4): 305–8.
6.
Christman MS, Chen JT, Holmes NM. Obstructive complications of lichen sclerosus.
J Pediatr Urol
. 2009 Jun; 5(3): 165–9.
7.
Stühmer A. Balanitis xerotica obliterans (post-operationem) und ihre Beziehungenzur “Kraurosis glandis et praeputii penis”.
Arch Dermatol Syph
. 1928; 156(3): 613–23.
8.
Celis S, Reed F, Murphy F, Adams S, Gillick J, Abdelhafeez AH, et al. Balanitis xerotica obliterans in children and adolescents: a literature review and clinical series.
J Pediatr Urol
. 2014 Feb; 10(1): 34–9.
9.
Neill SM, Lewis FM, Tatnall FM, Cox NH; British Association of Dermatologists. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010.
Br J Dermatol
. 2010 Oct; 163(4): 672–82.
10.
Becker K, Meissner V, Farwick W, Bauer R, Gaiser MR. Lichen sclerosus and atopy in boys: coincidence or correlation?
Br J Dermatol
. 2013 Feb; 168(2): 362–6.
11.
Jacobs L, Gilliam A, Khavari N, Bass D. Association between lichen sclerosus and celiac disease: a report of three pediatric cases.
Pediatr Dermatol
. 2014 Nov-Dec; 31(6):e128–31.
12.
Guarneri F, Giuffrida R, Di Bari F, Cannavò SP, Benvenga S. Thyroid Autoimmunity and Lichen.
Front Endocrinol (Lausanne)
. 2017 Jun; 8: 146.
13.
Homer L, Buchanan KJ, Nasr B, Losty PD, Corbett HJ. Meatal stenosis in boys following circumcision for lichen sclerosus (balanitis xerotica obliterans).
J Urol
. 2014 Dec; 192(6): 1784–8.
14.
Potts BA, Belsante MJ, Peterson AC. Intraurethral Steroids are a Safe and Effective Treatment for Stricture Disease in Patients with Biopsy Proven Lichen Sclerosus.
J Urol
. 2016 Jun; 195(6): 1790–6.
15.
Tong LX, Sun GS, Teng JM. Pediatric Lichen Sclerosus: A Review of the Epidemiology and Treatment Options.
Pediatr Dermatol
. 2015 Sep-Oct; 32(5): 593–9.
16.
Kirtschig G, Becker K, Gunthert A, Jasaitiene D, Cooper S, Chi CC, et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol. 2015 Oct; 29(10):e1–43.
17.
Smith YR, Quint EH. Clobetasol propionate in the treatment of premenarchal vulvar lichen sclerosus.
Obstet Gynecol
. 2001 Oct; 98(4): 588–91.
18.
Virgili A, Minghetti S, Borghi A, Corazza M. Long-term maintenance therapy for vulvar lichen sclerosus: the results of a randomized study comparing topical vitamin E with an emollient.
Eur J Dermatol
. 2013 Apr; 23(2): 189–94.
19.
Borghi A, Corazza M, Minghetti S, Toni G, Virgili A. Avocado and soybean extracts as active principles in the treatment of mild-to-moderate vulvar lichen sclerosus: results of efficacy and tolerability.
J Eur Acad Dermatol Venereol
. 2015 Jun; 29(6): 1225–30.
20.
Currò M, Russo T, Ferlazzo N, Caccamo D, Antonuccio P, Arena S, et al. Anti-Inflammatory and Tissue Regenerative Effects of Topical Treatment with Ozonated Olive Oil/Vitamin E Acetate in Balanitis Xerotica Obliterans.
Molecules
. 2018 Mar; 23(3):E645.
21.
Catterall RD, Oates JK. Treatment of balanitis xerotica obliterans with hydrocortisone injections.
Br J Vener Dis
. 1962 Jun; 38(2): 75–7.
22.
Pugliese JM, Morey AF, Peterson AC. Lichen sclerosus: review of the literature and current recommendations for management.
J Urol
. 2007 Dec; 178(6): 2268–76.
23.
Bochove-Overgaauw DM, Gelders W, De Vylder AM. Routine biopsies in pediatric circumcision: (non) sense?
J Pediatr Urol
. 2009 Jun; 5(3): 178–80.
24.
Naji H, Jawad E, Ahmed HA, Mustafa R. Histopathological examination of the prepuce after circumcision: is it a waste of resources?
Afr J Paediatr Surg
. 2013 Apr-Jun; 10(2): 164–6.
25.
Pradhan A, Patel R, Said AJ, Upadhyaya M. 10 Years’ Experience in Balanitis Xerotica Obliterans: A Single-Institution Study.
Eur J Pediatr Surg
. 2018, Epub ahead of print.
26.
Kiss A, Csontai A, Pirót L, Nyirády P, Merksz M, Király L. The response of balanitis xerotica obliterans to local steroid application compared with placebo in children.
J Urol
. 2001 Jan; 165(1): 219–20.
27.
Poindexter G, Morrell DS. Anogenital pruritus: lichen sclerosus in children.
Pediatr Ann
. 2007 Dec; 36(12): 785–91.
28.
Dahlman-Ghozlan K, Hedblad MA, von Krogh G. Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study [Level V].
J Am Acad Dermatol
. 1999 Mar; 40(3): 451–7.
29.
Edmonds E, Barton G, Buisson S, Francis N, Gotch F, Game L, et al. Gene expression profiling in male genital lichen sclerosus.
Int J Exp Pathol
. 2011 Oct; 92(5): 320–5.
30.
Chi CC, Kirtschig G, Baldo M, Lewis F, Wang SH, Wojnarowska F. Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus. J Am Acad Dermatol. 2012 Aug; 67(2): 305–12.
31.
Ebert AK, Rösch WH, Vogt T. Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study.
Eur Urol
. 2008 Oct; 54(4): 932–7.
32.
Marren P, Dean D, Charnock M, Wojnarowska F. The basement membrane zone in lichen sclerosus: an immunohistochemical study.
Br J Dermatol
. 1997 Apr; 136(4): 508–14.
33.
Oikarinen A, Sandberg M, Hurskainen T, Kinnunen T, Kallioinen M. Collagen biosynthesis in lichen sclerosus et atrophicus studied by biochemical and in situ hybridization techniques.
Acta Derm Venereol Suppl (Stockh)
. 1991; 162: 3–12.
34.
Coureau B, Bussières JF, Tremblay S. Cushing’s syndrome induced by misuse of moderate- to high-potency topical corticosteroids.
Ann Pharmacother
. 2008 Dec; 42(12): 1903–7.
35.
Smith SD, Hong E, Fearns S, Blaszczynski A, Fischer G. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups.
Australas J Dermatol
. 2010 Aug; 51(3): 168–74.
36.
Travagli V, Zanardi I, Bocci V. Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims.
Recent Pat Antiinfect Drug Discov
. 2009 Jun; 4(2): 130–42.
37.
Sechi LA, Lezcano I, Nunez N, Espim M, Duprè I, Pinna A, et al. Antibacterial activity of ozonized sunflower oil (Oleozon).
J Appl Microbiol
. 2001 Feb; 90(2): 279–84.
38.
Patel PV, Kumar V, Kumar S, Gd V, Patel A. Therapeutic effect of topical ozonated oil on the epithelial healing of palatal wound sites: a planimetrical and cytological study.
J Investig Clin Dent
. 2011 Nov; 2(4): 248–58.
39.
Wynn TA. IL-13 effector functions.
Annu Rev Immunol
. 2003; 21(1): 425–56.
40.
Dalessandri T, Crawford G, Hayes M, Castro Seoane R, Strid J. IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin.
Nat Commun
. 2016 Jun; 7(1): 12080.
41.
Gooding JM, Yap KL, Ikura M. The cadherin-catenin complex as a focal point of cell adhesion and signalling: new insights from three-dimensional structures.
BioEssays
. 2004 May; 26(5): 497–511.
42.
Neppelberg E, Loro LL, Oijordsbakken G, Johannessen AC. Altered CD40 and E-cadherin expression–putative role in oral lichen planus.
J Oral Pathol Med
. 2007 Mar; 36(3): 153–60.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.